Thats a frustrating reality for a lot of people, but understanding exactly how Humana approaches GLP-1 coverage helps you figure out your next move, whether thats appealing a denial, exploring employer plan options, or finding an affordable alternative
Tirzepatide, as a dual GIP/GLP-1 agonist, may produce slightly more pronounced effects because it typically produces greater weight loss (15% to 20% of body weight versus 10% to 15% for pure GLP-1 agonists) and more dramatic metabolic improvements
Avoid triggers such as spicy, fatty, greasy, and acidic foods
By now, most people are somewhat familiar with GLP-1 medications, a class of drugs that is helping millions of overweight and obese patients find weight loss success
And while the Grand Canyon-esque chasm in institutional ownership suggests NVO has far more potential upside if Wall Street latches on so far, thats not happening, as the institutional ownership percentage is a fifth of what it was at its June 2024 peak
Shipping was awesome came very well packed and quick